Previously a Managing Director, Camille Samuels is now an Affiliated Director with Versant Ventures and represents Versant on the Achaogen, Kythera Pharmaceuticals and Semprae Laboratories Boards.

Cami joined Versant shortly after its formation in early 2000. Prior to Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company’s clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.

Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow.

Current Versant Board Seats

Achaogen, Kythera Biopharmaceuticals, Semprae Laboratories

Previous Versant Board Involvement

Fluidigm – observer (public), Genomic Health – observer (public), NovaCardia (acquired), ParAllele (acquired), Syrrx – observer (acquired), Transcept Pharmaceuticals (public)